Sign in
Taking peopleNo phase

Following adults with primary membranous nephropathy over time to see how they do

Follows adults with primary membranous nephropathy to describe their long-term health outcomes.

Key facts

Who runs it
Mario Negri Institute for Pharmacological Research
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
An Outcome Analysis of Primary Membranous Nephropathy
Status
Recruiting
People taking part
500 people, planned
Started
29 Nov 2024
Expected to end
Jun 2054
Type of study
Observational
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary membranous nephropathy and nephrotic syndrome. It follows how their disease goes over time with treatment such as rituximab or other monoclonal antibodies.

Age
18 years and older
Sex
All sexes
Disease stage
Primary membranous nephropathy with nephrotic syndrome (protein in the urine above 3.5 g/24 hours).
Biomarker or test result
Proteinuria >3.5 g/24 hours (protein in the urine).

Main reasons for not taking part

  • People who cannot legally make their own decisions, fully or partly
  • Any reason a person cannot have rituximab or another monoclonal antibody

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adults (≥18 years old) on the day of signing informed consent
  • Diagnosis of primary membranous nephropathy
  • Nephrotic syndrome (proteinuria >3.5 g/24 hours)
  • Written informed consent to the use of recorded data for research purposes

Who cannot take part

  • Any contraindication to treatment with rituximab or other monoclonal antibody
  • Legal incapacity or limited legal capacity

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.

Read full original descriptionShow less

The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
Plain-language title
Following adults with primary membranous nephropathy over time to see how they doGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
23 March 2026